GODAVARI DRUGS LTD. SHARE PRICE [LIVE]

BSE: INE362C01012   NSE: GODAVARI   SECTOR: Pharma

OPEN YOUR FREE DEMAT ACCOUNT AND START TRADING SEAMLESSLY
Already an existing customer? - Login Now!
NSE
N/A
Change:
BSE
66.00
Change:
NSE
BSE Click here to view BSE data
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Open:
High:
Low:
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
P/E:
Div yield:

Fundamental analysis

Quality
Valuation
0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Stock
Sector
Sensex
Name Mar 21 Dec 20

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in GODAVARI DRUGS LTD.

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

GODAVARI News

Frequently Asked Questions

What is the Share price of GODAVARI DRUGS LTD. (GODAVARI)?

GODAVARI DRUGS LTD. (GODAVARI) share price as of September 28, 2022, on BSE is Rs 66.00 (BSE).

Can I buy GODAVARI DRUGS LTD. (GODAVARI) shares?

Yes, You can buy GODAVARI DRUGS LTD. (GODAVARI) shares by opening a Demat account with Angel One.

How do I buy GODAVARI DRUGS LTD. (GODAVARI) from Angel One?

GODAVARI DRUGS LTD. (GODAVARI) share can be brought through the following modes:
  1. Direct investment: You can buy GODAVARI DRUGS LTD. (GODAVARI) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to GODAVARI DRUGS LTD. (GODAVARI) shares.

In which sector do GODAVARI DRUGS LTD. (GODAVARI) belong?

GODAVARI DRUGS LTD. (GODAVARI) belongs to Pharma.

About GODAVARI

Today's live share price for GODAVARI DRUGS LTD. is NSE: N/A, BSE: ₹ 66.00 with a current market capitalization of .

Godavari Drugs is engaged in manufacturing drugs. Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand. The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.: 450 tpa) and diethyl oxalate, DEO (cap.: 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap.: 144 tpa). The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections. The backward integration into SMO and DEO will enhance value-addition. In fact, Siris and Chemox Chemicals, both having good capacities of SMX, have recently gone in for the production of SMO. In 2000 the company introduced 'Pyrazyamide' in the market. Since the product is being well accepted in the market the company is planning to increase the capacity of 'Pyrazyamide' of 180 TPA and have also finalised on other products Cislactum,which is a intermediate used to produce Diltiazem an anti anginal drug.

Read more